8-K - Advanced Biomed Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Advanced Biomed Inc. entered a definitive agreement to acquire 100% of Acellent Technologies (Hong Kong) Co. Limited for $1.08 million in stock, contingent on due diligence and regulatory approvals.

Key Takeaways

1Company agreed to acquire 100% equity interest in Acellent Technologies, a provider of AI-powered financial verification and audit solutions.

2Total consideration is 270,000 shares of common stock, valued at $4.00 per share for an aggregate estimated value of $1,080,000.

3Transaction closing is subject to completion of financial and legal due diligence and receipt of required regulatory approvals.

4The Share Purchase Agreement is dated April 2, 2026, with the seller identified as Xiaomin Chen.

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement.** On April 2, 2026, Advanced Biomed Inc. (the “Company”) entered into a Share Purchase Agreement (the “Agreement”) w

Material Agreement

$4.00$1.1M

Source Document

9.01

Financial Statement and Exhibits.** | Exhibit No. | | Description | |---|---|---| | 10.1 | | Share Purchase Agreement, dated April 2, 2026, by and among Advance

Exhibits Only

Transaction Details

Acquisition / Disposition

Target: Acellent Technologies (Hong Kong) Co. Limited
Consideration: 270,000 shares of Buyer's common stock valued at $4.00 per share (Aggregate estimated value: $1,080,000)
Structure: Purchase of 100% equity interest (10,000 ordinary shares)

•Closing date to be mutually agreed after conditions are met
•Completion of financial and legal due diligence reviews of the Target
•Receipt of any and all regulatory approvals required in connection with the Acquisition

Material Agreement

Agreement: Share Purchase Agreement
Parties: Advanced Biomed Inc. (Buyer), Acellent Technologies (Hong Kong) Co. Limited (Target), Xiaomin Chen (Seller)

•Seller agrees to sell 100% equity interest in Target
•Purchase Price: 270,000 shares of Buyer common stock
•Governing Law: State of New York
•Exclusive jurisdiction: Federal or State courts in New York, New York

Exhibits (2)

10.1

SHARE PURCHASE AGREEMENT, DATED APRIL 2, 2026, BY AND AMONG ADVANCED BIOMED INC., XIAOMIN CHEN AND ACELLENT TECHNOLOGIES (HONG KONG) CO. LIMITED

8-K

CURRENT REPORT